COVID-19 claims Cancer Research UK funding cuts, forecasting major shortfall

Cancer Research UK said COVID-19 will hit its ability to raise funds, prompting cuts. (Getty Images)

Cancer Research UK (CRUK) said it has been forced to take “the difficult decision” to make deep funding cuts across its grants and institutes as the fallout from the pandemic continues to affect all areas of biomedical research.  

CRUK, which funds around half of all oncology research in the U.K., said it will be axing funding to its “existing grants and institutes by up to 10% and its national network of Centres by around 20%.”

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

This tallies up to a loss of £44 million ($54 million) across its research portfolio for the year and comes as the charity, which also has a commercial arm, expects donations to fall hard this year.

Iain Foulkes, executive director of research and innovation at CRUK, said: “COVID-19 has left the whole world in uncharted waters. And the unprecedented measures to control the global COVID-19 pandemic have had a huge impact on both our researchers’ ability to carry on in the lab, and on our ability to fundraise. Faced with a predicted loss of 20-25% of fundraising income, we are forced to look for savings across our current portfolio."

He said making these sorts of cuts is “the most difficult decision we have had to make. We don’t do so lightly."

He added: “Cancer doesn’t go away during or after COVID-19, but we’re incredibly proud of our community of researchers who have been very quick to respond to the crisis, using their kit, skills and talent to support the NHS and the COVID-19 response. Our mission is so important to people all over the UK and by helping the global effort of tackling COVID-19, we hope we can get back to beating cancer as soon as possible.”

Suggested Articles

The Tel Aviv-based VC firm focused on digital health has closed a new fund totaling $170 million, with plans to expand to the Asia Pacific region.

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.